RAS/PI3K路径突变使上皮卵巢癌细胞对PARP/NAMPT抑制剂组合敏感
Michael Gruet1,2, Yitao Xu1, Lyutong An1
1Department of Surgery and Cancer, Imperial College London, London, UK.
Communications biology
|December 19, 2025
概括
PARP 抑制剂和 NAMPT 抑制剂的组合显示出对治疗三阴性乳腺癌和卵巢癌的前景. 这种疗法在具有RAS/PI3K通路突变的癌症中特别有效,提供了潜在的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 聚 (ADP-ribose) 聚合酶抑制剂 (PARPi) 和尼古丁胺胺酸转移酶抑制剂 (NAMPTi) 的组合正在针对各种癌症进行研究.
- 剂量限制性毒性限制了NAMPTi的临床使用.
- 识别预测性基因组生物标志物对于最大限度地提高NAMPTi的治疗窗口至关重要.
研究的目的:
- 为了确定NAMPTi疗效的预测性基因组生物标志物.
- 评估PARPi/NAMPTi组合在具有特定突变的上皮卵巢癌 (EOC) 中的疗效.
主要方法:
- 对EOC细胞系进行生物信息分析和查.
- 评估olaparib和FK866联合治疗对NMN,NAD+,ROS产生,DNA损伤和亡的影响.
- 评估不同细胞系中的酶3/7活性.
- 使用卵巢癌小鼠模型的体内研究.
主要成果:
- 具有RAS/PI3K通路突变的EOC细胞系对NAMPTi FK866.6具有敏感性.
- 联合olaparib和FK866治疗降低了NMN和NAD+水平,增加了ROS的产生,DNA损伤和亡.
- 在RAS/PI3K突变细胞系中,卡斯帕酶3/7活性显著上调.
- 组合疗法减少了瘤体重,并在临床前小鼠模型中改善了生存率.
结论:
- RAS/PI3K路径突变可以作为EOC中NAMPTi敏感性的预测生物标志物.
- 在具有RAS/PI3K突变的EOC临床前模型中,PARPi和NAMPTi的组合显示出显著的抗瘤活性.
- 这种联合治疗有可能成为针对特定卵巢癌亚型的向治疗策略.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K